Clinical trial
Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute…
NCT00345826 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00345826 |
|---|---|
| Title | Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia |
| Official title | Long-Term Safety and Efficacy of Dasatinib (BMS-354825) in Subjects Who Experienced Clinical Benefit on Protocol CA 180-002 |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 19 |
| Start date | Nov 1, 2005 |
| Primary completion | Jul 1, 2010 |
| First posted | Jun 29, 2006 |
| Last update posted | Jan 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: